Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Atezolizumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | sensitive | Atezolizumab | Guideline | Actionable | Tecentriq (atezolizumab) is included in guidelines as adjuvant therapy for non-small cell lung cancer patients with PD-L1 expression >/= 1% and negative for EGFR exon 19 deletion, L858R, or ALK rearrangements who have received prior adjuvant chemotherapy (NCCN.org). | detail... |
CD274 positive | lung non-small cell carcinoma | sensitive | Atezolizumab | FDA approved - On Companion Diagnostic | Actionable | In a Phase III trial (IMpower010) that supported FDA approval, adjuvant Tecentriq (atezolizumab) treatment following resection and chemotherapy improved disease-free survival compared to best supportive care (HR 0·66, p=0·0039) in patients with stage II-IIIA non-small cell lung cancer whose tumors expressed CD274 (PD-L1) on 1% or more of tumor cells (PMID: 34555333; NCT02486718). | detail... 34555333 detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... | |
Full reference... | ||
Tecentriq (atezolizumab) FDA Drug Label | Full reference... | |
(34555333) | Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. | Full reference... |